Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer.
$0.70+3.11%
报价 2026-11-06
市值
$1.8M
EV
$-2.1M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -97.2%
$0.64$24.64
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CLDICalidi Biotherapeutics, Inc. | $1.8M | +3.1% | – | 0% | – | – | – | |
| KZIAKazia Therapeutics Limited | $11.6M | +2.6% | – | 100% | – | – | – | |
| SNGXSoligenix, Inc. | $7.3M | +0.5% | 0.0% | 0% | – | – | – | |
| CNSPCNS Pharmaceuticals, Inc. | $5.7M | -2.2% | +75.9% | 0% | – | – | – | |
| XBIOXenetic Biosciences, Inc. | $4.4M | +0.3% | +20.0% | 100% | – | – | – | |
| CMNDClearmind Medicine Inc. | $2.8M | -4.6% | – | 0% | – | – | – | |
| CANFCan-Fite BioPharma Ltd. | $2.1M | +1.3% | – | 100% | – | – | – | |
| SXTP60 Degrees Pharmaceuticals, Inc. | $2.1M | -35.1% | +35.7% | 19.4% | – | – | – | |
| SILOSilo Pharma, Inc. | $1.5M | +3.1% | 0.0% | -474.3% | – | – | – | |
| 同行中位数 | – | – | +20.0% | 9.7% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。